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Introduction: Lactic acidosis is the most common cause of metabolic acidosis in hospitalized patients. It is
recognized as a potential complication of metformin use, particularly in patients with risk factors such as renal
dysfunction, liver disease, and heavy alcohol ingestion. These conditions are associated with systemic hypoxemia,
which may be caused by cardiorespiratory disease, major surgery, sepsis, dehydration, old age, and overdose. The
reported frequency of lactic acidosis is 0.06 per 1000 patient-years, mostly in patients with predisposing factors. This
case is important because it details the seriousness of metformin-associated lactic acidosis in a critically ill patient
and because, to the best of our knowledge, our patient survived with minimal residual defect despite experiencing
a cardiac arrest.
Case presentation: A 66-year-old Caucasian woman presented to our hospital with profound lactic acidosis, which
was initially thought to be ischemic gut. She then survived an in-hospital pulseless electrical activity arrest.
Conclusion: Metformin-associated lactic acidosis is a diagnosis by exclusion; however, a high degree of clinical
suspicion supplemented by prompt multisystem organ support can significantly influence the outcome in critically
ill patients.
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Metformin is an oral biguanide anti-diabetic agent. It is
a small, non-plasma-protein-bound molecule, and 90%
of metformin is excreted unchanged by the kidneys
through glomerular filtration and possibly through tubu-
lar secretion. In addition to being relatively safe, its use
has been advocated in the treatment of type 2 diabetes
in patients who are obese and has been shown to slow
cardiovascular complications associated with diabetes. By
decreasing excess hepatic gluconeogenesis without raising
insulin levels, it rarely leads to significant hypoglycemia
when used as monotherapy [1-3]. Therapy with metformin
has been associated with type B lactic acidosis.
Metformin-associated lactic acidosis (MALA) is a
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unless otherwise stated.reportedly has a mortality rate up to 50%. There has
been a serious debate about the exact role of metformin
in the development of lactic acidosis. The Cochrane
group [4], Comparative Outcomes Study of Metformin
Intervention versus Conventional Approach (COSMIC)
[5] study, and the United Kingdom Prospective Diabetes
study [6] have disputed the existence of lactic acidosis in
the presence of metformin and hence the term metformin-
induced lactic acidosis has subsequently been changed to
MALA. The independent effect of metformin on the devel-
opment of lactic acidosis remains unclear. Metformin re-
duces pyruvate dehydrogenase activity and mitochondrial
transport of reducing agents, and thus enhances anaerobic
metabolism. This shift to anaerobic metabolism, in the
presence of reduced insulin, increases production of pre-
cursors for the Krebs cycle. Consequently, there is a de-
creased ability to channel those precursors into aerobic
metabolism, which, in turn, results in increased metabol-
ism of pyruvate to lactate and increases net lactic acid
production. MALA has non-specific presenting features;ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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temic vascular resistance and respiratory failure.
A systematic review and meta-analysis showed no evi-
dence that metformin therapy is associated with an in-
creased risk of lactic acidosis or with increased levels of
lactate compared with other anti-hyperglycemic treat-
ments if the drug is prescribed under study conditions,
taking into account contraindications [7]. Of 194 studies
considered, there were no cases of fatal or nonfatal lactic
acidosis in 36,893 patient-years in the metformin group or
in 30,109 patient-years in the non-metformin group [7]. In
another review of 11,800 patients treated with metformin
for a mean of about two years in Saskatchewan, Canada,
only two patients developed lactic acidosis (incidence: nine
cases per 100,000 years of exposure) [8].
Case presentation
A 66-year-old Caucasian woman with type 2 diabetes
presented to our emergency department with a three-
week history of generalized malaise, associated poor oral
intake, and some diarrhea. Her enteric symptoms were
vague and unquantifiable. She was obese and had a
past medical history of poorly controlled type 2 dia-
betes for 15 years, hypertension, asthma, and depression.
Her regular medication comprised metformin 3g daily,
modified-release gliclazide 60mg daily, aspirin 100mg
daily, atorvastatin 40mg daily, ramipril 10mg daily, and
hydrochlorothiazide 25mg daily. Our patient was brought
into hospital by ambulance; her pre-hospital observations
were as follows: Glasgow Coma Scale score, 15; blood
sugar level, 2.8mmol/L; blood pressure, 90/40mmHg;
pulse, 54 beats per minute; respiratory rate, 32 breaths
per minute; and peripheral oxygen saturation, 98% on 8L
oxygen via a variable oxygen delivery mask. On arrival to
our emergency department, she was confused with a
Glasgow Coma Scale score of 14 out of 15 (E4V4M6), with
the rest of her physiological parameters similar to her pre-
hospital observations.
Her initial investigations were as follows: serum so-
dium, 140mmol/L (normal range: 137 to 145mmol/L);
serum potassium, 7.3mmol/L (normal range: 3.5 to
4.9mmol/L); serum chloride, 91mmol/L (normal range:
100 to 109mmol/L); serum bicarbonate, 1mmol/L (normal
range: 22 to 32mmol/L); anion gap, 55mmol/L (normal
range: 7 to 17mmol/L); serum glucose, 2.3mmol/L; urea,
30.8mmol/L (normal range: 2.7 to 8.0mmol/L); and serum
creatinine, 768umol/L (normal range: 50 to 100umol/L).
Results from liver function tests were normal. Her tropo-
nin level was 50ng/L (normal range: <30ng/L). Venous
blood gas measurements revealed a profound metabolic
acidemia: pH, 6.58; partial pressure of CO2, 38.6mmHg;
HCO3, 3.6mmol/L; glucose, 2.0mmol/L; and lactate,
16.7mmol/L. Her initial resuscitation strategy included
2000mL of 0.9% sodium chloride solution, 10mL of 10%calcium gluconate, 15 units insulin (Actrapid) in 50mL
50% dextrose, and 1mL/kg of 8.4% sodium bicarbonate
solution.
Minutes after these initial investigations, our patient
experienced a pulseless electrical activity cardiac arrest
and was managed as per advanced life support protocol.
She had a total downtime of 25 minutes. During cardio-
pulmonary resuscitation she was intubated and venti-
lated. Following return of spontaneous circulation, she
required an infusion of adrenaline for blood pressure
support. She had an unremarkable chest radiograph,
electrocardiogram, and toxicology screen.
With a presumed diagnosis of ischemic bowel based
on vague abdominal features and profound lactatemia,
our patient was admitted to our intensive care unit
(ICU) for preoperative optimization. In our ICU, she
was sedated and ventilated on an inspired oxygen con-
centration of 40% and on modest ventilator paramters
(peak inspiratory pressure <25cmH2O). To treat her se-
vere circulatory shock, she was fluid-resuscitated with a
total of 10,000mL crystalloid from a central venous pres-
sure of 8cmH2O to 16cmH2O. In addition, she required
very high doses of noradrenaline and adrenaline. Con-
tinuous veno-venous hemodiafiltration was commenced
at exchange rates of 50mL/kg/h using Hemosol B0 solu-
tion. She was empirically started on vancomycin and pi-
peracillin and tazobactam (Tazocin) as broad-spectrum
antimicrobial cover.
Our patient went to theater 26 hours post admission
for an exploratory laparotomy, which revealed no signifi-
cant findings. We continued her broad-spectrum anti-
microbial cover despite negative microbiological cultures.
Renal replacement therapy continued and our patient’s
acid-base balance slowly normalized over three days. Hav-
ing excluded all causes of a high anion gap lactic acidosis,
including negative red blood cell transketolase activity for
thiamine deficiency, we presumed our patient to have had
a severe MALA ‘triggered’ by an acute kidney injury from
dehydration. This was supported by a serum metformin
level of 4mg/L. Her renal function slowly improved with
continuous veno-venous hemodiafiltration and she slowly
recovered with a total of 35 days stay in ICU.
Discussion
A high anion gap metabolic acidosis commonly occurs
secondary to ketoacidosis (in diabetes, alcoholism, star-
vation), toxins (alcohol, ethylene, glycol, methanol, and
paraldehyde), kidney injury, and lactic acidosis (shock,
hypoxia, carbon monoxide, cyanide, and metformin).
A diagnosis of MALA should always form part of the
differential in a patient with high anion gap metabolic
acidosis. Even though MALA masquerading as an is-
chemic gut has previously been reported, our case is
different because our patient survived, as compared to
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posthumously [9].
Treatment of MALA is largely supportive, comprising
adequate resuscitation, treating any underlying con-
founding disease process, and renal replacement therapy
for acidosis and drug elimination. Lactic acidosis, though
extremely rare, is associated with 50% mortality. An ana-
lysis of 49 cases of lactic acidosis associated with metfor-
min use found the overall mortality was not correlated
with plasma lactate concentrations. Paradoxically, plasma
metformin concentrations were about three times higher
in patients who survived. All cases of lactic acidosis had,
in addition to metformin use, acute or chronic comorbidi-
ties predisposing to lactic acidosis, suggesting that lactic
acidosis may be coincidental rather than causally associ-
ated with metformin use [10]. Another case series con-
cluded that the extent of acidosis and accumulation of
metformin was less important than other coexisting fac-
tors [11]. A good predictive factor of death is an acute liver
dysfunction as assessed by prothrombin time.
Our patient had multiple risk factors, including renovas-
cular disease, an acute kidney injury from dehydration, and
continued intake of nephrotoxic angiotensin-converting
enzyme inhibitor and thiazide diuretic. In addition, she
had continued taking her usual metformin dose. We
believe that there was an accumulation of metformin
due to reduced renal clearance. Her severe lactic acidosis
with increasing inotrope requirement while in our ICU
led to an emergency laparotomy, which did not show any
intra-abdominal pathology. Her plasma metformin level
subsequently came back as 4mg/L, which is suggestive of
our diagnosis in the absence of any other cause in a pa-
tient presenting with a raised anion gap (44.6mmol/L)
metabolic acidosis. It is worth noting that the inci-
dence of MALA estimated from metformin serum con-
centration measurements in patients with type 2 diabetes
mellitus is 5 to 16 times higher than reported in the
literature [11].
Our case typifies MALA in that there were high serum
metformin levels, profound lactatemia in the presence
of an Acute kidney injury, and concurrent illness. In this
regard, is metformin causal, co-responsible, or coinci-
dental? The debate rages on.
Conclusion
MALA is rare but life threatening. Although controversy
surrounding causality exists, current guidelines advocate
metformin review and/or withdrawal for patients with
renal impairment, during periods of tissue hypoxia, two
days before general anesthesia, and for three days follow-
ing use of contrast-medium-containing iodine. Early
renal replacement therapy forms the mainstay of treatment
in critical illness because it provides both symptomatic and
etiological treatment by eliminating lactate and metformin,in addition to cardiorespiratory organ support. Goals of
supportive treatment are to maintain adequate tissue per-
fusion, correct electrolyte imbalance and hypoglycemia,
and perform mechanical ventilation in patients with re-
spiratory distress and hemodynamic instability.
Consent
Written informed consent was initially obtained from
the patient’s next of kin as the patient was too unwell to
sign a valid consent form at the time of obtaining the
consent. Subsequently, written informed consent was
also obtained from the patient as she had recovered
completely and was deemed to be mentally competent
to give her consent for her case to be published. A copy
of the written consent is available for review by the
Editor-in-Chief of this journal.
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